Selective depletion of alloreactive donor t cells with adenosine—clinical scale up for allogeneic stem cell transplantation

      Introduction: Selective depletion (SD) of alloreacting T cells from the stem cell transplant may prevent graft-versus-host disease while sparing T cells with useful reactivity against viruses and malignancy. Typical ex vivo approaches involve stimulating donor T cells with host antigen presenting cells (APCs) followed by targeted elimination of activated alloreacting donor T cells. We have recently shown efficient ex vivo removal of alloactivated T cells by the purine nucleotide adenosine (1–2 mM) while preserving quiescent lymphocytes which incorporate the antiviral and antileukemic repertoire. Here we present the clinical scale-up of this approach.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect